Medication adherence among adults prescribed imatinib, dasatinib, or nilotinib for the treatment of chronic myeloid leukemia

Journal of Oncology Pharmacy Practice

Volumn 21, Issue 1, 2015, Pages 19-25

  Anderson, Kristin R ^a   Chambers, Carole R ^b   Lam, Nadine ^b   Yau, Patrick S ^b   Cusano, Frances ^b   Savoie, M Lynn ^b   Sheikh, Naureen ^b  

^a FOOTHILLS HOSPITAL   (Canada)

^b TOM BAKER CANCER CENTRE   (Canada)

Author keywords

Cancer; chronic myeloid leukemia; dasatinib; imatinib; nilotinib; oncology; oral chemotherapy; patient adherence

Indexed keywords

DASATINIB; IMATINIB; INTERFERON; NILOTINIB; 4-METHYL-N-(3-(4-METHYLIMIDAZOL-1-YL)-5-(TRIFLUOROMETHYL)PHENYL)-3-((4-PYRIDIN-3-YLPYRIMIDIN-2-YL)AMINO)BENZAMIDE; ANTINEOPLASTIC AGENT; BENZAMIDE DERIVATIVE; PIPERAZINE DERIVATIVE; PYRIMIDINE DERIVATIVE; THIAZOLE DERIVATIVE;

ADULT; ADULT DISEASE; AGE DISTRIBUTION; AGED; ARTICLE; BONE MARROW SUPPRESSION; CANCER CHEMOTHERAPY; CANCER IMMUNOLOGY; CHRONIC MYELOID LEUKEMIA; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; DESCRIPTIVE RESEARCH; DIARRHEA; FATIGUE; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD REVIEW; MEDICATION COMPLIANCE; MYALGIA; NAUSEA; PATIENT COMPLIANCE; PERIORBITAL EDEMA; RASH; RETROSPECTIVE STUDY; THORAX PAIN; ADOLESCENT; AGE; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; MIDDLE AGED; STATISTICS AND NUMERICAL DATA; VERY ELDERLY; YOUNG ADULT;

ADOLESCENT; ADULT; AGE FACTORS; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; BENZAMIDES; CROSS-SECTIONAL STUDIES; FEMALE; HUMANS; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; MALE; MEDICATION ADHERENCE; MIDDLE AGED; PIPERAZINES; PYRIMIDINES; RETROSPECTIVE STUDIES; THIAZOLES; YOUNG ADULT;

EID: 84920545106     PISSN: 10781552     EISSN: 1477092X     Source Type: Journal    
DOI: 10.1177/1078155213520261     Document Type: Article

References (23)

1. Cortes J, Silver RT, Kantarjian HM Holland-Frei cancer medicine. 8 th ed. CT: Shelton, 2010. CT: Shelton ; 2010 :
2. Van Etten R. Clinical manifestation and diagnosis of 3 chronic myeloid leukemia. In: Larson R (ed.) Uptodate, Waltham, MA: www.uptodate.com (accessed 29 May 2012).
3. De Almeida MH, Barbosa Pagnano KB, Sanches Souza HA, et al. Adherence to tyrosine kinase inhibitors (TKI) in chronic myeloid leukemia (CML) seems to be related to duration of treatment and type of TKI. Haematologica. 2010 ; 95: 343-343
4. Druker BJ, Guilhot F, O'Brien SG, et al. Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. N Engl J Med. 2006 ; 355: 23-23
5. Marin D, Bazeos A, Mahon FX, et al. Adherence is the critical factor for achieving molecular responses in patients with chronic myeloid leukemia who achieve complete cytogenetic responses on imatinib. J Clin Oncol. 2010 ; 28: 2381-2388
6. Ganesan P, Sagar TG, Dubashi B, et al. Nonadherence to imatinib adversely affects event free survival in chronic phase chronic myeloid leukemia. Am J Hematol. 2011 ; 86: 471-474
7. Ibrahim AR, Eliasson L, Apperley JF, et al. Poor adherence is the main reason for loss of CCyR and imatinib failure for chronic myeloid leukemia patients on long-term therapy. Blood. 2011 ; 117: 3733-3736
8. Breccia M, Efficace F, Alimena G. Imatinib treatment in chronic myelogenous leukemia: what have we learned so far?. Cancer Lett. 2011 ; 300: 115-121
9. Wu EQ, Johnson S, Beaulieu N, et al. Healthcare resource utilization and costs associated with non-adherence to imatinib treatment in chronic myeloid leukemia patients. Curr Med Res Opin. 2010 ; 26: 61-69
10. Wu EQ, Bollu VK, Guo A, et al. Non-adherence to imatinib in chronic myeloid leukemia patients is associated with a short term and long term negative impact on healthcare utilization and costs. Blood. 2009 ; 114: abstract 4270 - abstract 4270
11. Darkow T, Henk HJ, Thomas SK, et al. Treatment interruptions and non-adherence with imatinib and associated healthcare costs: a retrospective analysis among managed care patients with chronic myelogenous leukaemia. Pharmacoeconomics. 2007 ; 25: 481-496
12. Horne R, Weinman J, Barber N, et al. Concordance, adherence and compliance in medicine taking. Report for the National Co-ordinating Centre for NHS Service Delivery and Organisation R & D (NCCSDO). December 2005, http://www.netscc.ac.uk/hsdr/files/project/SDO-FR-08-1412-076-V01.pdf (2005, accessed 30 May 2012).
13. Wei G, Rafiyath S, Liu D. First-line treatment for chronic myeloid leukemia: dasatinib, nilotinib, or imatinib. J Hematol Oncol. 2010 ; 3: 47-47
14. Noens L, Van Lierde MA, De Bock R, et al. Prevalence, determinants, and outcomes of nonadherence to imatinib therapy in patients with chronic myeloid leukemia: the ADAGIO study. Blood. 2009 ; 113: 5401-5411
15. Marin D. Current status of imatinib as frontline therapy for chronic myeloid leukemia. Semin Hematol. 2010 ; 47: 312-318
16. Eliasson L, Clifford S, Barber N, et al. Exploring chronic myeloid leukemia patients' reasons for not adhering to the oral anticancer drug imatinib as prescribed. Leuk Res. 2011 ; 35: 626-630
17. Peterson AM, Nau DP, Cramer JA, et al. A checklist for medication compliance and persistence studies using retrospective databases. Value Health. 2007 ; 10: 3-12
18. Vermeire E, Hearnshaw H, Royen V, et al. Patient adherence to treatment: three decades of research. A comprehensive review. J Clin Pharm Ther. 2001 ; 26: 331-342
19. Doti C, Stemmelin G, Shanley C, et al. Cytogenetic response in relation to the adherence to treatment with imatinib mesylate: a case control study. Blood. 2007 ; 110: 4553-4553
20. St Charles M, Bollu V, Hornyak E, et al. Predictors of treatment non-adherence in patients treated with imatinib mesylate for chronic myeloid leukemia. Blood. 2009 ; 114: 2209-2209
21. Cortes JE, Jones D, O'Brien S, et al. Results of dasatinib therapy in patients with early chronic-phase chronic myeloid leukemia. J Clin Oncol. 2010 ; 28: 398-404
22. Saglio G, Kim DW, Issaragrisil S, et al. Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia. N Engl J Med. 2010 ; 362: 2251-2259
23. Haynes RB, Ackloo E, Sahota N, et al. Interventions for enhancing medication adherence. Cochrane Rev. 2008 ; 4: 1-159